Disclosed are memory-regulating agents and methods that target actin binding LIM protein family, member 3 (ABLIM3). Specifically, the disclosure provides methods of inhibiting Ablim3 using inhibitory nucleic acids that target the Ablim3 gene or mRNA to improve memory in subjects with memory dysfunction associated with Alzheimer's Disease (AD), normal aging, or posttraumatic stress disorder (PTSD). Further disclosed is a cell-based assay that can be used to screen for small molecule regulators of Ablim3 function.
MOLECULAR RE-ENGINEERING OF EXCITATION-INHIBITION BALANCE IN MEMORY CIRCUITS